Introduction: Sacral nerve stimulation was FDA approved in 1997 .SNS is a
continuous electrical stimulation of the sacral nerves to inhibit or
activate the neural reflexes that influence the bladder, sphincter
and pelvic floor. Basically, a pacemaker-like implantable neurostimulator
Methods: This is a prospective study review a No. of patients, who received
SNM in Neuoscience Teaching Hospital and Ibn Sena Hospital
between May 2015 and May 2017. All two-stage procedures were
performed according to strict protocol of patients’ selection and
follow-up. Data of perioperative and postoperative complications
and their management were collected.
Results: Of the 55 patients that went through test stimulation, 45 were
implanted with SNM. 80% were female (36) and 20% were male
(9) , mean age was 35, Urine Incontinence(UI) patients had 4±2
leaks/day, and Urine frequency (UF) subjects had 16±4 voids/day.
Urine Retention (UR) patients had 4±2 self-catheterization\day
.The study that includes all patients with SNM implant with diary
data at baseline and 12 months showed an Over Active Bladder
(OAB) therapeutic success rate of 72% at 12 months and Under
Active Bladder therapeutic success rate of 75%. UI patients had a
mean reduction of 1?±?1 leaks/day; UF subjects had a mean
reduction of 8?±?4 voids/day. UR patients had 1?±?1 self-
catheterization\day patients showed significant improvement from
baseline. Device-related adverse events occurred in 18% (10/45)
of patients during test stimulation and 35% (16/45) of patients post implant
Conclusions: This multicenter study shows that sacral neuromodulation had
sustained efficacy and quality of life improvements, and it had a
safety profile through 12 month in patients with lower urinary tract
dysfunction.
Patient Care: Even younger patient below 45 can get benfit from SNM
Learning Objectives: Overactive bladder is responsing the most than underactive
bladder for SNM